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Letters to the Editors
Therapies used in rheumatology 
with relevance to coronavirus 
disease 2019
Sirs,
With the ongoing coronavirus disease 
2019 (COVID-19) pandemic and growing 
evidence suggesting a role for some drugs 
commonly used in the context of rheumatic 
diseases, both colleagues and patients are 
coming to us with questions about these 
claims. Despite the fact that evidence is 
still scarce, it is pertinent to be able to ad-
dress these queries in light of our previous 
experience in handling these prescriptions 
and take part in the multidisciplinary care of 
COVID-19 patients.
Two of the most commented therapeutic 
options are chloroquine and hydroxychlo-
roquine. A Chinese study demonstrated in 
vitro inhibition of SARS-CoV-2 by chloro-
quine (1). Multiple clinical trials are ongo-
ing in China, with news briefing of interim 
results derived from more than 100 patients 
demonstrating chloroquine phosphate as su-
perior to control in inhibiting the exacerba-
tion of pneumonia, improving lung imaging 
findings, promoting a virus negative conver-
sion and shortening the disease course (2). 
Accordingly, the Chinese Diagnosis and 
Treatment Protocol for Novel Coronavirus 
Pneumonia recommends chloroquine phos-
phate in its general treatment section (3). 
Concerning hydroxychloroquine, a Chinese 
study found it to be more potent than chlo-
roquine in vitro, and a French open label 
non-randomised clinical trial reported a sig-
nificant viral load reduction in COVID-19 
patients treated with hydroxychloroquine, 
with this effect reinforced with the associa-
tion of azithromycin (4, 5).
Another interesting option is tocilizumab, 
with the Chinese Diagnosis and Treatment 
Protocol for Novel Coronavirus Pneumo-
nia introducing the possibility of its use in 
patients with extensive lung lesions and se-
vere cases with increased levels of IL-6 (3). 
A preprint of a Chinese retrospective study 
evaluating treatment with tocilizumab in 21 
patients with severe COVID-19 (chinaX-
iv:202003.00026), described symptoms, 
hypoxemia and imaging improvement in 
most patients, with no adverse drug reac-
tions reported. An interesting correspond-
ence in the Lancet emphasised the accumu-
lating evidence suggesting a subgroup of 
severe COVID-19 patients that might have 
cytokine storm syndrome (6). The authors 
denote similitudes between the cytokine 
profile of these patients and patients with 
secondary haemophagocytic lymphohis-
tiocytosis (sHLH), suggesting the possi-
bility of using a score originally intended 
to recognise sHLH patients to identify the 
subgroup of severe COVID-19 patients for 
whom immunosuppression could be benefi-
cial (6). A trial evaluating the efficacy and 
safety of tocilizumab in COVID-19 is on-
going in China (ChiCTR2000029765). 
Baricitinib also raised some attention after 
a correspondence published in the Lancet 
featured artificial intelligence predicting the 
possibility of this drug reducing the ability 
of the virus to infect lung cells (7). The ra-
tionale for this hypothesis is based on the 
fact that angiotensin-converting enzyme 
2 might be used as a receptor by SARS-
CoV-2 to enter cells, and one of the known 
regulators of this receptor-mediated endo-
cytosis is the AP2-associated protein kinase 
1 (AAK1), which is inhibited by baricitinib 
(7). To the best of our knowledge, however, 
there are no other publications on baricitinib 
in the context of COVID-19.
Lastly, corticosteroids, which, according to 
current guidance by CDC and WHO, should 
be avoided in the management of COV-
ID-19 patients, based on the negative expe-
rience derived from SARS-Cov and MERS-
Cov patients (no survival benefit, increased 
side effects and delayed viral clearance) (8, 
9). If indicated for other reasons (such as 
chronic obstructive lung disease exacerba-
tion, asthma or septic shock), administra-
tion should be evaluated on an individual 
basis. Nevertheless, the Chinese Diagnosis 
and Treatment Protocol for Novel Corona-
virus Pneumonia includes the possibility 
of administering a corticosteroid course in 
patients with progressive deterioration of 
oxygenation, rapid imaging progression 
and excessive inflammatory response (3). 
Inclusively, a Chinese study reporting out-
comes of COVID-19 patients describes, 
among those with acute respiratory distress 
syndrome, a decrease in the risk of death 
with methylprednisolone (10). Multiple 
clinical trials are ongoing in China to assess 
the safety and efficacy of corticosteroids in 
COVID-19.
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